Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease.
Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease.
复制标题
DOI:
10.1073/pnas.1810470115
复制
发表时间:
2018-09-25
影响因子:
11.1
通讯作者:
Weber MS
中科院分区:
文献类型:
--
作者:
Häusler D;Häusser-Kinzel S;Feldmann L;Torke S;Lepennetier G;Bernard CCA;Zamvil SS;Brück W;Lehmann-Horn K;Weber MS
B cell depletion via anti-CD20 monoclonal antibodies is a novel, highly efficient therapy for multiple sclerosis (MS). In a murine MS model, we investigated three mechanistic questions that cannot be addressed in humans. First, we established that a fraction of mature B cells in the spleen is resistant to anti-CD20. Second, we determined that, after cessation of treatment, splenic and bone-marrow B cells reconstitute in parallel, substantially preceding B cell reappearance in blood. Third, we observed that, in a model involving activated B cells, the post–anti-CD20 B cell pool contained an elevated frequency of differentiated, myelin-reactive B cells. Together, our findings reveal mechanisms by which pathogenic B cells may persist in anti-CD20 treatment. The anti-CD20 antibody ocrelizumab, approved for treatment of multiple sclerosis, leads to rapid elimination of B cells from the blood. The extent of B cell depletion and kinetics of their recovery in different immune compartments is largely unknown. Here, we studied how anti-CD20 treatment influences B cells in bone marrow, blood, lymph nodes, and spleen in models of experimental autoimmune encephalomyelitis (EAE). Anti-CD20 reduced mature B cells in all compartments examined, although a subpopulation of antigen-experienced B cells persisted in splenic follicles. Upon treatment cessation, CD20+ B cells simultaneously repopulated in bone marrow and spleen before their reappearance in blood. In EAE induced by native myelin oligodendrocyte glycoprotein (MOG), a model in which B cells are activated, B cell recovery was characterized by expansion of mature, differentiated cells containing a high frequency of myelin-reactive B cells with restricted B cell receptor gene diversity. Those B cells served as efficient antigen-presenting cells (APCs) for activation of myelin-specific T cells. In MOG peptide-induced EAE, a purely T cell-mediated model that does not require B cells, in contrast, reconstituting B cells exhibited a naive phenotype without efficient APC capacity. Our results demonstrate that distinct subpopulations of B cells differ in their sensitivity to anti-CD20 treatment and suggest that differentiated B cells persisting in secondary lymphoid organs contribute to the recovering B cell pool.
登录
查看更多内容
影响因子:
9.9
作者:
Salzer J;Svenningsson R;Alping P;Novakova L;Björck A;Fink K;Islam-Jakobsson P;Malmeström C;Axelsson M;Vågberg M;Sundström P;Lycke J;Piehl F;Svenningsson A
通讯作者:
Svenningsson A
影响因子:
--
作者:
Jacob, Anu;Weinshenker, Brian G.;Cree, Bruce A. C.
通讯作者:
Cree, Bruce A. C.
影响因子:
11.2
作者:
Weber, Martin S.;Prod'homme, Thomas;Patarroyo, Juan C.;Molnarfi, Nicolas;Karnezis, Tara;Lehmann-Horn, Klaus;Danilenko, Dimitry M.;Eastham-Anderson, Jeffrey;Slavin, Anthony J.;Linington, Christopher;Bernard, Claude C. A.;Martin, Flavius;Zamvil, Scott S.
通讯作者:
Zamvil, Scott S.
影响因子:
15.9
作者:
Chamberlain, Nicolas;Massad, Christopher;Meffre, Eric
通讯作者:
Meffre, Eric
影响因子:
11.2
作者:
Hawker, Kathleen;O'Connor, Paul;Smith, Craig H.
通讯作者:
Smith, Craig H.